Navigation Links
Omeros Announces Successful Completion of PDE10 Phase 1 Multiple Ascending Dose Trial
Date:3/26/2013

ts show that OMS824, at well-tolerated doses, achieves concentrations that are anticipated to effectively inhibit PDE10 and support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders.

"These results are exciting – it appears that OMS824 is able to achieve significantly higher concentrations at the target enzyme in the brain than other PDE10 inhibitors being developed across the industry without incurring the movement abnormalities seen with those other compounds," stated Gregory A. Demopulos , M.D., chairman and chief executive officer of Omeros. "While wrapping up the Phase 1 program, we are aggressively advancing OMS824 into Phase 2 trials. Our initial focus will be Huntington's disease, for which we will be requesting orphan drug as well as Fast Track designations from the FDA, and a Phase 2a trial in patients with schizophrenia is expected to follow shortly thereafter. In addition to our progress in the OMS824 program, we plan to submit the NDA next quarter and the MAA mid-year for OMS302, our ophthalmic drug product, and we remain on track to advance our MASP-2 and PDE7 programs into the clinic in the coming months."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Cognitive dysfunction is responsible for substantial disability in these diseases and is not improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve psychiatric manifestations, such as the positive (e.g., halluci
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Elucidates Mechanism of its PDE7 Inhibitors in Addiction
2. Omeros to Present at the Cowen and Company 33rd Annual Health Care Conference
3. Omeros Announces Toxicology Study Data from MASP-2 Inhibitor
4. Omeros Announces Positive OMS302 Safety Data in Phase 3 Clinical Trial
5. Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program
6. Omeros to Present at the 24th Annual Piper Jaffray Health Care Conference
7. Omeros is Not Aware of Any Justification for Share Price Movement
8. Omeros Corporation Reports Third Quarter 2012 Financial Results
9. Omeros Responds to Misleading Announcement by Davis Wright Tremaine Concerning Settlement with Former Chief Financial Officer
10. Omeros Ophthalmology Product OMS302 Successful in Second Phase 3 Clinical Trial
11. Omeros Files Investigational New Drug Application for Lead Compound in PDE10 Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... Kingdom , Oct. 30, 2014 Molecular ... CBRX ) and Maryland ... developers with improved efficiency during clinical development that will ... next week. This partnership extends ... platform, which it launched earlier this month. The company ...
(Date:10/30/2014)... Oct. 30, 2014   Auxilium Pharmaceuticals , ... integrated specialty biopharmaceutical company, today announced financial results ... The Company highlighted important corporate, commercial, regulatory and ... "We are very pleased with the continued ... products in our portfolio this quarter, especially the ...
(Date:10/30/2014)... 30, 2014 Today, DripDrop, the first ... it was awarded a two-year contract, effective Sept. ... that serves the more than 100,000 members and ... and Provista.  DripDrop also received ... member hospitals who attended the recent Novation 2014 ...
Breaking Medicine Technology:Molecular Profiles To Launch US Strategic Alliance At AAPS 2Molecular Profiles To Launch US Strategic Alliance At AAPS 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 2Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 3Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 4Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 5Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 6Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 7Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 8Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 9Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 10Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 11Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 12Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 13Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 14Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 15Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 16Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 17Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 18Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 19Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 20Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 21Auxilium Pharmaceuticals, Inc. Announces Third Quarter 2014 Financial Results 22DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 2DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 3DripDrop Partners With Novation To Help Hospitals Address I.V. Saline Solution Shortages; ORS Product Used For Ebola Outbreak 4
... 27, 2011 Inovio Pharmaceuticals, Inc. (NYSE Amex: ... synthetic immunogens against cancers and infectious diseases, announced today ... Development Agreement (CRADA) with the United States Department of ... Animal Disease Center. This collaboration will evaluate the efficacy ...
... Co., Inc. (NYSE Amex: TPI ), a pharmaceutical ... branded generics and other pharmaceuticals, announced the financial results for ... year 2011 ending June 30 ... delivered $95.2 million, exceeding the guided $90.0 million revenue forecast ...
Cached Medicine Technology:Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 2Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 3Inovio Pharmaceuticals Enters Collaboration With U.S. Dept. of Homeland Security to Assess Foot & Mouth Disease Synthetic Vaccines' Potential to Help Ensure Nation's Food Supply Safety 4TPI Reports Fiscal Year 2011 Financial Results 2TPI Reports Fiscal Year 2011 Financial Results 3TPI Reports Fiscal Year 2011 Financial Results 4TPI Reports Fiscal Year 2011 Financial Results 5TPI Reports Fiscal Year 2011 Financial Results 6TPI Reports Fiscal Year 2011 Financial Results 7TPI Reports Fiscal Year 2011 Financial Results 8TPI Reports Fiscal Year 2011 Financial Results 9TPI Reports Fiscal Year 2011 Financial Results 10TPI Reports Fiscal Year 2011 Financial Results 11
(Date:10/31/2014)... are clear differences in the brains of people with ... new research indicates. Scientists at Stanford University ... diagnose this baffling condition and shed light on how ... misdiagnosed or labeled as hypochondriacs. Using three ... [chronic fatigue syndrome] patients, brains diverge from those of ...
(Date:10/31/2014)... HealthDay Reporter THURSDAY, Oct. ... to appear in the United States, a new U.S. government ... the United States each year, researchers at the U.S. Centers ... 250,000 cases that occurred worldwide in 2008, according to the ... disease that causes skin sores, nerve damage, and muscle weakness ...
(Date:10/31/2014)... By Steven Reinberg HealthDay ... skin condition eczema may increase slightly the risk of broken bones ... of 34,500 adults, researchers found that among 7 percent of people ... had a bone or joint injury and 0.6 percent had an ... people without eczema, those with the skin condition had more than ...
(Date:10/30/2014)... NY)—Investigators at Albert Einstein College of Medicine ... Center will present their latest aging research ... Annual Scientific Meeting. Topics include the identification of ... for cognitive impairment and the cellular biology of ... 2014 in Washington, D.C., "Einstein-Montefiore has distinguished itself ...
(Date:10/30/2014)... at least 2 years old to be covered by ... guidance exists other than the general recommendation by national ... least the first six months. , So what ... that motivated researchers at the University at Buffalo School ... patterns of American infants at 6 months and 12 ...
Breaking Medicine News(10 mins):Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 2Health News:Brain Scans Yield Clues to Chronic Fatigue Syndrome 3Health News:Leprosy Still Occurs in U.S., CDC Reports 2Health News:Leprosy Still Occurs in U.S., CDC Reports 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 2Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 3Health News:Einstein-Montefiore investigators present aging research at Gerontological Society of America's Annual Scientific Meeting 4Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 2Health News:What do American babies eat? A lot depends on Mom's socioeconomic background 3
... , New research reveals that a persons socioeconomic status ... After reviewing 20 years of medical literature regarding the ... adults, researchers from LDS Hospital and the University of ... correlation between the two, even after adjusting for smoking ...
... 2007 - Oakland, CA Childrens Hospital & Research ... $9 million funding award from the National Institutes of ... in collaboration with Children,s Hospital Oakland Research Institute, was ... which supports innovative hands-on programs that encourage children to ...
... Tobacco Cessation,Campaign, HARRISBURG, Pa., Nov. 13 As ... eight residents,who are willing to document their attempts to ... Cancer Society,s annual event, held on the third Thursday,in ... the hope that they will,stop using tobacco for good., ...
... BASKING RIDGE, N.J., Nov. 13 Millennium,Biotechnologies ... Bulletin Board: MBTG), today announced that it had ... exclusive provider of,nutritional products to Provider Services Inc. ... with PSI purchasing Millennium,s,Resurgex Select(TM) line of products. ...
... End of 2007 and the Rest by Q1 2008., ... Active Directory Tasks and ... 13 Chip PC industry-leading,thin client solutions were chosen ... of North Rhine-Westphalia County to,supply 20,000 thin clients and ...
... 13 Cardinal Health today,announced an exclusive alliance ... helps eligible health care facilities implement,manage and meet ... Pricing Program. The 340B Drug Pricing Program ... federally qualified health care facilities provide care,for the ...
Cached Medicine News:Health News:National Institutes of Health selects Children's Hospital Oakland for grant award 2Health News:State Health Officials Seek Quitters as Part of Great American Smokeout 2Health News:Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio 2Health News:Millennium Biotechnologies Inc. Signs Five Year $20,000,000 Purchase Agreement with Provider Services Inc. of Cleveland, Ohio 3Health News:Chip PC Wins Europe's Largest Thin Client Tender to Supply 20,000 Thin Clients and Management Software to German RZF - Financial Administration of North Rhine-Westphalia County 2Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 2Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 3Health News:Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: